Trial reportJournal of cosmetic dermatology2026
Liposomal Delivery Enhances the Effects of a Collagen Tripeptide-Containing Formulation on Dermal Structure and Optical Skin Parameters: A Randomized, Double-Blind, Placebo-Controlled Trial.
Trial report in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06771388 (Efficacy Evaluation of Avance QQ Collagen for Skin Beautification), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy Evaluation of Avance QQ Collagen for Skin Beautification
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to determine whether liposomal delivery enhances the effects of a collagen tripeptide-containing formulation on dermal structural and biomechanical parameters, as well as appearance-related skin properties, compared with a nonliposomal formulation and placebo.
methodsIn a randomized, double-blind, placebo-controlled trial, 75 healthy adults aged 25-65 years were assigned to receive placebo, a nonliposomal formulation containing collagen tripeptides, or a liposomal formulation containing collagen tripeptides (50 mL/day) for 8 weeks. Objective assessments of dermal collagen density, skin hydration, elasticity, wrinkle area, skin luminance, and tone evenness were performed at baseline and Weeks 2, 4, and 8 using standardized instrumental measurements.
resultsBoth collagen tripeptide-containing formulation groups showed significant improvements in dermal collagen density, hydration, and elasticity compared with placebo (p < 0.05). The liposomal formulation demonstrated an earlier onset and a greater magnitude of improvement across multiple parameters, with a statistically significant advantage in skin elasticity at Week 8 compared with the nonliposomal formulation (p < 0.05). Notably, only the liposomal collagen tripeptide-containing formulation group exhibited a significant reduction in wrinkle area at Week 8 relative to placebo (p < 0.05). Both collagen tripeptide formulation groups also showed significant increases in skin luminance and tone evenness.
conclusionLiposomal delivery significantly enhances the functional effects of a collagen tripeptide-containing formulation on dermal structure and biomechanical performance, particularly dermal collagen density and skin elasticity, as well as optical skin properties including luminance and tone evenness. These findings support the application of liposomal formulations containing collagen tripeptides as an effective oral nutricosmetic strategy for improving visible signs of skin aging.
trial registrationClinicalTrials.gov identifier: NCT06771388.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.